CURB found longer progression-free survival overall with added SBRT, with different findings in its lung and breast cohorts. The small breast comparison did not show a statistically significant improvement.
Open-label randomised phase 2 comparison after at least first-line systemic therapy in metastatic breast cancer or non-small-cell lung cancer with no more than five progressing lesions. The 2024 report randomised 106 patients: 51 to standard care and 55 to SBRT plus standard care. The primary endpoint was progression-free survival; the registry defines its clock from randomisation. Disease-site subgroup analysis was prespecified.
The overall median was 7.2 months with added SBRT versus 3.2 with standard care, hazard ratio 0.53. The NSCLC subgroup showed a longer median, while the breast subgroup’s estimate was imprecise and not statistically significant. Sixteen of 47 breast participants had TNBC; the combined breast result does not determine the effect in every subtype.
Supports a setting-specific comparison of adding SBRT. Neither treated-site control nor this progression endpoint alone establishes an immune mechanism or a universal survival benefit.
Shares Systemic versus local therapy, SBRT / SABR (stereotactic radiotherapy), Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Systemic versus local therapy, Non-small-cell lung cancer and the tags education-audit, local-treatment.
Shares Systemic versus local therapy, Breast cancer (all types) and the tags education-audit, local-treatment.
Shares SBRT / SABR (stereotactic radiotherapy), Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Shares Breast cancer (all types) and the tags education-audit, local-treatment.
Shares CURB: SBRT for oligoprogressive breast or non-small-cell lung cancer, Breast cancer (all types).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/